The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I / Insulin hybrid receptor.本發明係關於可以特別與人類的第一型類胰島素生長因子受體(IGF-IR)結合的新穎抗體。本發明同樣地包括使用這些抗體為藥劑來預防及/或治療，因由IGF1及/或IGF2所剌激，做過度表現IGF-IR之癌細胞，或任何與該受體過度表現有關病變的預防及/或治療，以及與IGF-IR及/或IGF-I/胰島素混種受體過度表現相關病變的診斷程序或配套工具。
